drugset / Trial / NCT03859869
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2022-03-23
- Completion
- 2022-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pancrelipase | Protein / enzyme biologic | 12000 iu | Oral |
| Subject | Pancrelipase | Protein / enzyme biologic | 72000 iu | Oral |